WO2025181155 - HUMAN BETA-GLUCOCEREBROSIDASE BINDERS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/181155
Publication Date
04.09.2025
International Application No.
PCT/EP2025/055198
International Filing Date
26.02.2025
Title **
[English]
HUMAN BETA-GLUCOCEREBROSIDASE BINDERS AND USES THEREOF
[French]
LIANTS DE BÊTA-GLUCOCÉRÉBROSIDASE HUMAINE ET LEURS UTILISATIONS
Applicants **
VIB VZW
VRIJE UNIVERSITEIT BRUSSEL
UNIVERSITÀ DEGLI STUDI DI PADOVA
Inventors
VERSÉES, Wim
DAL MASO, Thomas
PLOTEGHER, Nicoletta
GREGGIO, Elisa
SINISGALLI, Chiara
Priority Data
24159588.3
26.02.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2770 | |
| EPO | Filing, Examination, Granting | 11150 | |
| Japan | Filing, Examination, Granting | 2174 | |
| South Korea | Filing, Examination, Granting | 2050 | |
| USA | Filing, Examination, Granting | 6990 |
Total:
25,134
Contact Us
Abstract[English]
This application relates to polypeptide agents and compositions specifically binding human beta-glucocerebrosidase (GCase, GBA1). Particularly, immunoglobulin single variable domains (ISVDs) are described which allosterically bind human GCase, thereby positively modulating GCase in its stability and/or catalytic activity. The invention relates further to vectors and nucleic acids encoding such ISVD-based modulators. Also encompassed are compositions, in particular pharmaceutical compositions, containing such ISVD modulators. The GCase-specific allosteric modulators, specifically the ISVDs and compositions described herein, may be used for prevention and/or treatment of GCase-related diseases, including Gaucher disease (GD) and Parkinson's disease (PD).[French]
La présente invention concerne des agents polypeptidiques et des compositions se liant spécifiquement à la bêta-glucocérébrosidase humaine (GCase, GBA1). En particulier, l'invention concerne des domaines variables uniques d'immunoglobuline (ISVD) qui se lient de manière allostérique à la GCase humaine, ce qui permet de moduler positivement la GCase au niveau de sa stabilité et/ou de son activité catalytique. L'invention concerne en outre des vecteurs et des acides nucléiques codant pour de tels modulateurs à base d'ISVD. L'invention concerne également des compositions, en particulier des compositions pharmaceutiques, contenant de tels modulateurs ISVD. Les modulateurs allostériques spécifiques de la GCase, en particulier les ISVD et les compositions décrites ici, peuvent être utilisés pour la prévention et/ou le traitement de maladies associées à la GCase, notamment la maladie de Gaucher (MG) et la maladie de Parkinson (MP).